Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
The aim of this study is to observe the efficacy, safety, postoperative pathological response rate and survival benefit of RC48 combined withSintilimab and chemotherapy in perioperative therapy of locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.
Gastric Cancer
DRUG: RC48 combined with Sintilimab and XELOX
pathological complete response (pCR) rate, The percentage of patients with no residual cells at the primary cancer site and N(-) per histological evaluation., Up to approximately 12 weeks
R0 resection rate, The percentage of patients who have no residual cancer cells (gross or microscopically) at the resection margins., Up to approximately 12 weeks|Disease free survival (DFS), DFS is defined as the time from postoperative baseline imaging evaluation to disease recurrence or death in subjects who are disease-free after surgery., From randomization to the date of recurrence or death (up to approximately 4 years).|Major pathological response (MPR) rate, Up to approximately 12 weeks|Clinical downgrading rate, Up to approximately 12 weeks|Overall survival (OS), OS is defined as the time from the first dose to all-cause death., From the randomization to the date of death (up to approximately 4 years).|Percentage of Participants who experience one or more adverse events (AEs)., The incidence and grade of adverse events (including SAE) will be determined per NCI-CTCAE 5.0., Up to approximately 2 years
The aim of this study is to observe the efficacy, safety, postoperative pathological response rate and survival benefit of RC48 combined withSintilimab and chemotherapy in perioperative therapy of locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.